• Cytos Biotechnology Ltd., of Zurich, Switzerland, said the Swiss Takeover Board approved an exemption allowing the investors in its CHF37 million (US$40.6 million) recapitalization to hold more than one-third of the company's outstanding shares when the financing closes.